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Re: ‘Prothrombin G20210 Mutation and Lower Extremity
Peripheral Arterial Disease: A Systematic Review and
Meta-analysis’
Vasquez et al.1 showed that prothrombin G20210 mutation
is signiﬁcantly elevated in patients with peripheral occlusive
arterial disease (POAD) suffering from critical limb ischemia
(CLI) but not in the others. Interestingly, this mutation has
been reported to be more prevalent in patients with
Buerger’s disease.2,3 Avcu et al.2 found an increased fre-
quency of the G20210 mutation in Buerger’s disease (OR
7.98, 2.45e25.13). Buerger’s disease is characterized by
diffuse arterial thrombosis and a severe clinical picture,
most often at the CLI stage. In a recently published case
control study among patients with premature POAD the
author’s team found that G20210 mutation was signiﬁcantly
more frequent in Buerger’s disease (4.2% vs. 1.7 in con-
trols).3 This difference was not found for atherosclerosis
related POAD (2.6%). When compared with the 64 POAD
patients, the 49 with Buerger’s disease had CLI in 88%
versus 28% in atherosclerosis related POAD. As suggested
by Vasquez et al.,1 G20210 mutation might be one among
several factors favouring thrombosis and leading to CLI in
POAD, and prospective cohort studies would be useful to
evaluate the role of this mutation to predict progression in
POAD.
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Response to ‘Re: Prothrombin G20210A Mutation and
Lower Extremity Peripheral Arterial Disease. A Systematic
Review and Meta-analysis’
We read with interest the letter by Boulon et al.1 The pro-
posed association between prothrombin G20210A and
thromboangiitis obliterans is very interesting. Prior studies
have suggested that prothrombin G20210A interacts with
other cardiovascular risk factors (especially smoking) to in-
crease the risk of vascular events,2 and this interaction could
further explain the association of prothrombin G20210A and
thromboangiitis obliterans seen by Bérard et al. and Avcu et
al.3,4 The literature search conducted in our systematic re-
view did not identify the study by Bérard et al.3,5; had the
study been included there would have been no changes in
the association of lower extremity peripheral arterial disease
(PAD) prothrombin G20210A (pooled random effect odds
ratio 1.68 [95% conﬁdence interval 0.94e3.00]; I2 52.1%; p
¼ .08). Furthermore, the addition of the study by Bérard et
al. does not modify the association between prothrombin
G20210A and critical limb ischemia secondary to PAD (even
in the absence of positive cases).3 Finally, we agree that
well-designed prospective cohort studies are needed to
evaluate the role of prothrombin G20210A in the progres-
sion and outcome of patients with PAD.
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